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Objective. To determine the prevalence of left ventricular hypertrophy (LVH) and its associated risk factors in lupus nephritis (LN)
patients. Methods. 287 LN patients (age: 38.54 ± 13.31, 262 female) were recruited. Echocardiography and serum high-sensitivity
C-reactive protein (hs-CRP) were measured. Their relationship was evaluated by univariate correlation analysis and multivariate
regression analysis. Results. The prevalence of LVH in this cohort was 21.25% (n = 61). Serum hs-CRP level was signiﬁcantly
elevatedinpatientswithLVHcomparedtothosewithout(8.03(3.22–30.95)versus3.93(1.48–9.48)mg/L,P<. 01),andcorrelated
with left ventricular mass index (LVMI) (r = 0.314, P = .001). Multivariate regression analysis further conﬁrmed that hs-CRP was
an independent risk factor (β = 0.338, P = .002) for LVH in patients with LN. Conclusions. Our ﬁndings demonstrated that serum
hs-CRP level is independently correlated with LVMI and suggested that measurement of hs-CRP may provide important clinical
information to investigate LVH in LN patients.
1.Introduction
Alterations in left ventricular structure and function have
been reported among the cardiac manifestations of systemic
lupus erythematosus (SLE), especially in those who have
renal complications. These alterations include echocardio-
graphic evidence of increases in LV wall thicknesses and
mass, a decrease in LV ejection fraction, and impaired dias-
tolic ﬁlling [1–3]. However, it is currently uncertain whether
these abnormalities are disease-related eﬀects or a result
of other predisposing conditions, such as inﬂammation,
hypertension, anemia, and disorder of mineral metabolism.
In recent years, there has been a growing interest in
the hypothesis that atherosclerosis may be an inﬂammatory
disease. It has been noted that C-reactive protein (CRP), a
marker of the reactant plasma protein component of the
inﬂammatory response, is a major predictor of cardiovas-
cular disease (CVD) in apparently healthy subjects [4–6].
Previous reports have found the association between CRP
and left ventricular hypertrophy (LVH) in several pathologic
states such as hypertension, insulin resistance, and chronic
kidneydisease(CKD)[7–9].Inthisstudy,weinvestigatedthe
potentialinterrelationshipsamonghs-CRPs,amoresensitive
marker of systemic inﬂammation and LV mass index (LVMI)
in patients with lupus nephritis (LN) by using the clinical
cutoﬀ levels of CRP.
2. Methods
2.1. Study Subjects. A total of 287 incipient LN patients were
consecutively enrolled from January 2005 to December 2008.
All participants met the diagnostic criteria of the Ameri-
can College of Rheumatology [10, 11]. Exclusion criteria
included ischemic heart disease, acute coronary syndrome,
congestive heart failure (CHF) (New York Heart Association
(NYHA)classIIorgreater),oldcerebralinfarction,historyof
transient ischemic attack, secondary hypertension, receipt of
any immunosuppressant and/or an anti-inﬂammatory drug
(aspirin or nonsteroidal anti-inﬂammatory drug (NSAID)),
chronic infection, cancer, and pregnancy. Participants with
moderate or severe aortic or mitral regurgitation were also
excluded.Thestudyprotocolwasapprovedbythelocalethics
committee, and all participants gave their written informed
consent to participate in this study.2 Journal of Biomedicine and Biotechnology
Table 1: Baseline characteristics of LN patients with and without echocardiographic LVH.
Baseline characteristics Echo-LVH (n = 61) Normal LVMI (n = 226)
Gender, male, % 8.85 8.20
Age, y 40.92 ±14.16
∗ 35.43 ±11.88
BMI, kg/m2 21.48 ±3.10 22.10 ±3.63
Smoke history, % 17.69 18.03
SBP, mmHg 140.00 (120.00–155.00) 130.00 (110.00–140.00)
DBP, mmHg 87.00 (80.00–91.60) 85.00 (75.00–90.00)
MABP, mmHg 103.33 (93.33–113.97) 98.33 (88.33–110.00)
Hemoglobin level, g/L 90.62 ±22.99
∗∗ 105.95 ±22.43
ESR, mm/h 57.00 (26.00–85.00) 43.00 (21.00–73.00)
hs-CRP, mg/L 8.03 (3.22–30.95)
∗∗ 3.93 (1.48–9.48)
Serum albumin, g/L 30.03 ±6.34 33.26 ±6.06
Triglyceride, mmol/L 2.25 ±1.16 2.42 ±1.10
Cholesterol, mmol/L 5.47 ±1.99 5.64 ±2.12
Lipoprotein(a), mg/L 328.90 ±45.62 276.14 ±21.66
GFR, ml/min/1.73m2 66.05 ±4.68
∗ 90.24 ±4.52
Uric acid, mmol/L 491.78 ±29.35
∗ 402.44 ±17.03
Calcium, mmol/L 2.07 ±0.22 2.07 ±0.20
Phosphate, mmol/L 1.59 ±0.64 1.43 ±0.36
24 hours urine protein, g/24h 3.37 ±2.27 3.00 ±2.62
ds-DNA (%) 32 (82.05) 145 (90.06)
ANA (%) 43 (91.49) 180 (93.75)
ACL (%) 6 (26.08) 23 (17.69)
Complement C3, g/L 0.54 (0.38–0.83) 0.48 (0.37–0.65)
Fibrinogen, g/L 3.77 ±1.47 3.87 ±1.40
Echo-LVH: echocardiographic LVH; SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean arterial blood pressure; ESR: erythrocyte
sedimentation rate; GFR: glomerular ﬁltration rate; ANA: antinuclear antibody; ACL antiphospholipid antibody. Case number and positive incidenceo fd s -
DNA, ANA, and ACL was presented here in the table. Compared with normal LVMI, ∗P<. 05, ∗∗P<. 01.
2.2. Baseline Clinical Characteristics. After fasting overnight,
BP was measured with an appropriate arm cuﬀ and a
mercury column sphygmomanometer on the left arm after a
resting period of at least 10min in the supine position. After
BP measurement, venous blood sampling was performed in
all subjects. Height and body weight were measured, and
body mass index was calculated. The following parameters
were also determined: serum creatinine, serum lipids includ-
ing cholesterol, triglyceride, and lipoprotein(a), measure-
ment of serum complement C3 and C4, high-sensitivity C-
reactive protein, and antibody testing. Estimated glomerular
ﬁltration rate (eGFR) was calculated by MDRD formula.
High-sensitivity CRP (hs-CRP) was measured by autoim-
mune scattering rate nephelometry (BNP nephelometer,
Dade Behring). If hs-CRP level was >10mg/L, the test was
repeated. Antinuclear antibodies (ANA) were detected by
indirect immunoﬂuorescence (IIF). Double-stranded DNA
(ds-DNA) was detected by FARR assay (EUROIMMUN
AG, Germany), and antiphospholipid antibodies (ACL)
were measured by Enzyme-Linked Immunosorbent Assay
(ELISA) (EUROIMMUN AG, Germany).
2.3. Echocardiographic Methods and Calculation of Derived
Variables. Echocardiography was performed by an experi-
enced research technician using standard techniques who
was unaware of the clinical characteristics of the patients.
Studies were performed using phased-array echocardiog-
raphy with M-mode, 2-dimensional, pulsed, and color-
ﬂow Doppler capabilities. LV mass (LVM) was cal-
culated using the following formula: LVM=0.8 (1.04
(LVST+LVPWT+LVDd)3−LVDd3)+ 0.6, where LVST is LV
septal wall thickness, and LVPWT is LV posterior wall
thickness, LVDd is LV diastolic diameter. LVMI was indexed
for body surface area (BSA), and LVH was deﬁned by an
LVMI of over 110 g/m2 in women and 125g/m2 in men [12].
2.4. Statistical Analysis. Data were described as means ±
SDs for those with normal distribution and as medians
andinterquartilerangesforasymmetricaldistribution.Com-
parisons between patients divided by CRP cutoﬀ level and
with or without LVH were performed by unpaired t-tests
in normally distributed data and by nonparametric Mann-
Whitneytestinasymmetricallydistributeddata,orbyX2 test
in categorical data. The cut-oﬀ level of hs-CRP was deﬁned
accordingtotheAHA/CDCrecommendations[13],inwhich
CRP levels ≥3mg/L were deﬁned as average- and high-
risk groups for CVD. Bivariate relationships with LV mass
were assessed using the Spearman correlation coeﬃcient. All
variables that had signiﬁcant relations were evaluated for
inclusion in a model predicting LV mass using multivariable
regression analysis; unstandardized regression coeﬃcients
(B) with their 95% conﬁdence intervals were reported. AllJournal of Biomedicine and Biotechnology 3
Table 2: Laboratory parameters of LN patients grouped by hs-CRP level.
Baseline characteristics CRP ≥ 3mg/dl(n = 198) CRP < 3mg/dl(n = 89)
Gender, male, % 8.59 8.98
Age, y 39.37 ±14.09
∗ 34.97 ±11.56
BMI, kg/m2 22.29 ±3.18 21.67 ±3.07
Smoke history, % 18.18 16.86
SBP, mmHg 132.90 (120.00–148.10) 130.00 (117.50–150.00)
DBP, mmHg 86.00 (79.50–94.40) 83.50 (73.75–90.00)
MABP, mmHg 103.33 (90.00–110.64) 97.5( 8 9 .08–110.83)
Hemoglobin level, g/L 93.04 ±24.91
∗∗ 106.57 ±23.65
ESR, mm/h 56.00 (31.50–83.00)
∗∗ 32.00 (19.75–58.50)
Serum albumin, g/L 27.70 ±7.03 33.09 ±6.95
Triglyceride, mmol/L 2.48 ±1.32 2.46 ±1.06
Cholesterol, mmol/L 5.60 ±1.89
∗ 6.41 ±2.76
Lipoprotein(a), mg/L 275.99 ±28.90 281.15 ±31.16
GFR, ml/min/1.73m2 73.45 ±4.62 82.11 ±5.75
Uric acid, mmol/L 463.96 ±17.85 421.40 ±19.48
Calcium, mmol/L 2.04 ±0.22 2.12 ±0.16
Phosphate, mmol/L 1.68 ±0.80 1.53 ±0.29
24 hours urine protein, g/24h 3.00 ±2.62 3.37 ±2.27
ds-DNA (%) 124 (88.57) 53 (88.33)
ANA (%) 148 (91.36) 73 (94.81)
ACL (%) 20 (20.00) 9 (16.98)
Complement C3, g/L 0.44 (0.34–0.76) 0.43 (0.32–0.64)
Fibrinogen, g/L 4.17 ±1.60
∗∗ 3.54 ±1.12
SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean arterial blood pressure; ESR: erythrocyte sedimentation rate; GFR: glomerular
ﬁltration rate; ANA: antinuclear antibody; ACL: antiphospholipid antibody. Case number and positive incidence of ds-DNA, ANA and ACL was presented
here in the table. Compared with hs-CRP ≥ 3mg/L,∗P<. 05, ∗∗P<. 01.
of the statistics were performed by SPSS version 13.0, and
a 2-tailed P<. 05 was considered to indicate statistical
signiﬁcance.
3. Results
3.1. Description of LN Patients. The 287 subjects were
predominantly female (91.29%), with a mean age of 38.5 ±
13.3 at their entry. Totally 223/239 patients (93.30%) showed
positive ANA, 177/200 patients (88.50%) had positive ds-
DNA, and 29/153 patients (18.95%) showed ACL antibodies.
Renal biopsy was obtained from 135 (47.04%) patients,
which showed minimal mesangial LN (class I) in 4 (3.0%),
mesangial proliferative LN (class II) in 7 (5.2%), focal LN
(class III) in 16 (11.9%), diﬀuse LN (class IV) in 77 (57.0%),
membranous LN (class V) in 28 (20.7%), and advanced
sclerotic LN (class VI) in 3 (2.2%) patients according to
InternationalSocietyofNephrology/RenalPathologySociety
(ISN/RPS) 2003 classiﬁcation [14].
3.2. Prevalence of LVH in LN Patients. LVH was diagnosed
in 61 LN patients (21.25%). We compared the baseline
characteristics of patients with and without LVH, as showed
in Table 1. Patients with LVH were much older, had
signiﬁcantly elevated hs-CRP level and higher uric acid
level, lower hemoglobin level, and eGFR. However, BMI,
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Figure 1: Comparison of LVMI in two groups divided by hs-CRP
cutoﬀ level.
blood pressure, and serum lipids were not signiﬁcantly
diﬀerent between the two groups. Meanwhile, autoantibody
parameter positive incidence including ds-DNA, ANA, and
ACL did not diﬀer between patients with and without LVH.4 Journal of Biomedicine and Biotechnology
Table 3: Individual correlates of LVMI among LN patients.
rP
Age 0.154 .048
BMI −0.171 .030
SBP 0.214 .006
DBP 0.156 .045
MABP 0.183 .018
Hemoglobin −0.304 <.001
ESR 0.081 .314
Hs-CRP 0.225 .014
Serum albumin −0.107 .177
Triglyceride −0.035 .666
Cholesterol −0.015 .850
Lipoprotein(a) 0.043 .607
GFR −0.292 <.001
Uric acid 0.202 .011
Calcium 0.097 .451
Phosphate 0.065 .614
24 hours urine protein 0.091 .263
Ds-DNA −0.086 .351
ANA −0.099 .260
ACL 0.139 .232
Complement C3 −0.07 .394
Fibrinogen −0.04 .646
SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean
arterial blood pressure; ESR: erythrocyte sedimentationrate; GFR: glomeru-
lar ﬁltration rate; ANA: antinuclear antibody; ACL: antiphospholipid
antibody.
3.3.Associationbetweenhs-CRPandLVH. Tofurtherexplore
theextenttowhichinﬂammationaugmentLVH,thepatients
were subdivided into low- and average-to-high risk groups
according to hs-CRP cutoﬀ level. Among those who had
higher hs-CRP levels (≥3mg/L), LVMI was signiﬁcantly
increased (132.68 ± 57.84 versus 113.67 ± 29.17, P = .018)
(Figure 1). In addition, these patients had elder age (39.37 ±
14.09 versus 34.97 ± 11.55, P = .02), lower hemoglobin
level (93.04 ± 24.91 versus 106.57 ± 23.65, P<. 001), lower
cholesterol level (5.60 ± 1.89 versus 6.41 ± 2.76, P = .018),
higherESR(56.00 (31.50–83.00)versus32.00 (19.75–58.50),
P<. 001) and higher serum ﬁbrinogen level (4.17 ± 1.59
versus 3.54 ± 1.12, P = .004) (Table 2).
In univariate analysis involving the entire sample
(Table 3), signiﬁcant correlates of LVMI included age, body
mass index, blood pressure, hemoglobin level, hs-CRP, uric
acid level, and eGFR. After introducing all these signiﬁcant
variables into multivariate regression analysis, hs-CRP (β =
0.228, P = .009), along with uric acid (β = 0.382,P<. 001),
was further conﬁrmed to have positive associations with
LVMI.
4. Discussion
Our cross-sectional study revealed a linear relationship
between low-grade chronic inﬂammation estimated by high-
sensitivity CRP levels and LVMI, independent of several
other important covariates, such as adipose tissue distri-
bution BMI, BP levels, serum lipids, renal function, age,
and gender. The observation of this independent association
between hs-CRP level and LVMI is consistent with previous
ﬁndings [15, 16], and the present study extended to LN
patients. As far as we know, these ﬁndings are new and
potentially important for reﬁning CVD risk stratiﬁcation in
this population.
At the initial stage of the atherosclerotic process, systemic
inﬂammation would appear most importantly associated
with subclinical cardiovascular disease development, such
as LVH occurrence. A raised baseline CRP value has been
associated with inﬂammation, endothelial dysfunction, obe-
sity [17], the metabolic syndrome [18, 19], diabetes mellitus
[20], insulin resistance [7], and severity of hypertension
[21], and thus, various metabolic disorders may occur
by increasing CRP level and simultaneously promote an
increase in LV mass. On the other hand, local CRP synthesis
and secretion by smooth muscle cells, including those of
the human coronary artery, have been suggested to play an
i m p o r t a n tr o l ea sw e l l[ 22]. It is possible to speculate that
CRP may play a direct role in promoting LVH through these
mechanisms,including(1)increasingphosphatidylinositol3-
kinase activity [23];(2) upregulating inducible nitric oxide
synthase, certain cell signal transduction pathways including
the mitogen-activated protein kinase pathway, and nuclear
factor κ-B; (3) upregulating angiotensin II type 1 receptor
in vascular smooth muscle cells, and directly quenching
the production of nitric oxide by endothelial cells [24, 25],
resulting in increased production of endothelin-1 [26]; (4)
elevation of von Willebrand factor [27], which is known
to be associated with endothelial dysfunction. Thus, cardiac
hypertrophy may be, at least in part, attributable to an
increaseinCRPitself,viaactivatedtranscriptionalregulatory
mechanisms, proinﬂammatory and proatherogenic eﬀects,
and stimulation of endothelial dysfunction.
Some limitations of this study are important to note.
First, it is not possible to conclude from this observational
research whether CRP stimulates higher LVMI or whether
CRP is increased before the development of LVH. The
cross-sectional design prevents the demonstration of the
mechanisms by which LVH is related to inﬂammation.
These speculations should be addressed in futureprospective
longitudinal studies. Second, it may be better to introduce
SLEDAI score into multivariate regression analysis to further
estimatetheeﬀectofdiseaseitselfonLVH,andinﬂammation
status as well. Third, it is very regrettable that some of our
patients’ autoantibodies data were missing and incomplete.
Thiscohortwillbefollowedandexpandedtofurtherobserve
the prevalence and correlative factors of LVH, especially after
intervention therapy.
5. Conclusions
In conclusion, in LN subjects initially free of CVD, hs-CRP
showed a signiﬁcant association with LVMI, which suggested
that assessment of hs-CRP level may help to reﬁne CVD risk
stratiﬁcation in this population.Journal of Biomedicine and Biotechnology 5
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